# A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease

> **NCT03056742** · PHASE2 · WITHDRAWN · sponsor: **Stempeutics Research Pvt Ltd**

## Conditions studied

- Critical Limb Ischemia Due to Buerger's Disease

## Interventions

- **BIOLOGICAL:** Stempeucel(R)

## Key facts

- **NCT ID:** NCT03056742
- **Lead sponsor:** Stempeutics Research Pvt Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-02-20
- **Primary completion:** 2018-04
- **Final completion:** 2019-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Form 46 from DCGI for the manufacturing \& commercial marketing of Stempeucel® directs Stempeutics to conduct PMS study. Hence this study is being terminated.
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03056742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03056742, "A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03056742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*